Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy.

Elinor Ben-MenachemHans Peter GrebeKiyohito TeradaLori JensenTing LiMarc De BackerBjörn Steiniger-BrachTeresa GasallaMelissa BrockVictor Biton

Published in: Epilepsia (2019)

Long-term (median ~2 years) lacosamide monotherapy was efficacious and generally well tolerated in adults with newly diagnosed epilepsy. Seizure freedom rates were similar with lacosamide and carbamazepine-CR.

Keyphrases

newly diagnosed
combination therapy
open label
temporal lobe epilepsy